Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study

Wang, Ruixi; Liu, Shiliang; Chen, Baoqing; Li, Qiaoqiao; Cheng, Xingyuan; Zhu, Yujia; Zhang, Li; Hu, Yonghong; Liu, Mengzhong; Hu, Yingying; Xi, Mian

doi:10.1038/s41416-024-02779-4

Br J Cancer

2024

DOI: 10.1038/s41416-024-02779-4

|View full text |Cite

Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study

Ruixi Wang,

Shiliang Liu,

Baoqing Chen

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers

Jin,

Mou,

Zhou

et al. 2024

Cancer Control

View full text Add to dashboard Cite

Background Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop a predictive model to evaluate the survival benefits of immune therapy in patients with cholangiocarcinoma. Methods This retrospective analysis included 120 cholangiocarcinoma patients from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with survival following immune therapy. A predictive model was constructed and validated using calibration curves (CC), decision curve analysis (DCA), concordance index (C-index), and receiver operating characteristic (ROC) curves. Results Cox regression analysis identified several factors as potential predictors of survival post-immune therapy in cholangiocarcinoma: treatment cycle (<6 vs ≥ 6 months, 95% CI: 0.119-0.586, P = 0.001), neutrophil-to-lymphocyte ratio (NLR <3.08 vs ≥ 3.08, 95% CI: 1.864-9.624, P = 0.001), carcinoembryonic antigen (CEA <4.13 vs ≥ 4.13, 95% CI: 1.175-5.321, P = 0.017), and presence of bone metastasis (95% CI: 1.306-6.848, P = 0.010). The nomogram model achieved good predictive accuracy with a C-index of 0.811. CC indicated strong concordance between the predicted and observed outcomes. Multi-timepoint ROC curves at 1, 2, and 3 years validated the model’s performance (1-year AUC: 0.906, 2-year AUC: 0.832, 3-year AUC: 0.822). The multi-timepoint DCA curves also demonstrated a higher net benefit compared to extreme curves. Conclusion The nomogram model, incorporating key risk factors for cholangiocarcinoma patients post-immune therapy, demonstrates robust predictive accuracy for survival outcomes, offering the potential for improved clinical decision-making.

show abstract

Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers

Jin,

Mou,

Zhou

et al. 2024

Cancer Control

View full text Add to dashboard Cite

show abstract

Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape

Cheng,

Meng,

Wang

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background The clinical significance of immuno-inflammatory indicators and the underlying biological basis in patients with esophageal squamous cell carcinoma (ESCC) who receive chemoradiotherapy (CRT) combined with immunotherapy remains unclear. This study aims to evaluate the prognostic value of immuno-inflammatory biomarkers, develop a prognostic model, and explore the underlying mechanisms. Methods This study included 212 ESCC patients who received CRT and anti-PD-1 immunotherapy. Association between progression-free survival (PFS) and immuno-inflammatory biomarkers, including absolute lymphocyte count (ALC), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio was analyzed. A nomogram was built based on the independent prognostic factors identified using multivariable Cox regression model. Pre-treatment tumor samples from 47 patients were collected for RNA sequencing to investigate the immune-related tumor microenvironment. Results Patients experienced significant changes in immuno-inflammatory biomarkers during CRT, which gradually recovered after radiotherapy. Body mass index < 18.5 (HR, 1.85; P = 0.032), N3 stage (HR, 2.41; P = 0.002), high pre-CRT PLR (HR, 1.53; P = 0.037), low ALC nadir (HR, 1.84; P = 0.006), and high post-CRT NLR (HR, 2.12; P = 0.002) were independent prognostic factors for unfavorable PFS, which were incorporated into a nomogram with a concordance index of 0.70 (95% CI, 0.67–0.72). High-risk patients stratified by the nomogram had worse survival and were associated with lower levels of leukocyte and T cell activation, proliferation, and migration and less intratumoral immune cell infiltration. Conclusions Pre-CRT PLR, ALC nadir during CRT, and post-CRT NLR were significantly associated with PFS in patients with ESCC receiving CRT and immunotherapy. A nomogram model with good prognostic ability was developed. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-024-13298-z.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study

Cited by 2 publications

References 35 publications

Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers

Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers

Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape

Contact Info

Product

Resources

About